SG11201808777UA - Improvements in cancer treatment - Google Patents
Improvements in cancer treatmentInfo
- Publication number
- SG11201808777UA SG11201808777UA SG11201808777UA SG11201808777UA SG11201808777UA SG 11201808777U A SG11201808777U A SG 11201808777UA SG 11201808777U A SG11201808777U A SG 11201808777UA SG 11201808777U A SG11201808777U A SG 11201808777UA SG 11201808777U A SG11201808777U A SG 11201808777UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- turramurra
- unless
- box
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110101111111110111011111111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number ..... .....1 (43) International Publication Date WO 2017/173474 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: A61K 31/352 (2006.01) A61K 47/46 (2006.01) A61K 31/382 (2006.01) A61K 9/02 (2006.01) A61K 31/473 (2006.01) A61P 35/00 (2006.01) A61K 47/44 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (21) International Application Number: PCT/AU2016/050674 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 28 July 2016 (28.07.2016) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: 62/318,946 6 April 2016 (06.04.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) Applicant: NOXOPHARM LIMITED [AU/AU]; PO Box 824, Turramurra, New South Wales 2074 (AU). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventor: KELLY, Graham; PO Box 824, Turramurra, Declarations under Rule 4.17: New South Wales 2074 (AU). — of inventorship (Rule 4.17(iv)) (74) Agent: FPA PATENT ATTORNEYS PTY LTD; Level 46, 101 Collins Street, Melbourne, Victoria 3000 (AU). Published: Designated States (unless otherwise indicated, for every (81) — with international search report (Art. 21(3)) kind of national protection available): AE, AG, AL, AM, Il 7r IN 7r M IN 11 IN 11 © \" (54) Title: IMPROVEMENTS IN CANCER TREATMENT (:) .,.. (57) : The invention relates to cancer therapy, especially to cytotoxic agents and chemo-sensitizing and radio-sensitising agents, particularly isoflavonoids, and to improving the bioavailability of same.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662318946P | 2016-04-06 | 2016-04-06 | |
PCT/AU2016/050674 WO2017173474A1 (en) | 2016-04-06 | 2016-07-28 | Improvements in cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808777UA true SG11201808777UA (en) | 2018-11-29 |
Family
ID=60000141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808777UA SG11201808777UA (en) | 2016-04-06 | 2016-07-28 | Improvements in cancer treatment |
Country Status (11)
Country | Link |
---|---|
US (2) | US20190160004A1 (en) |
EP (2) | EP3439651A4 (en) |
JP (1) | JP2019510830A (en) |
KR (1) | KR20190016017A (en) |
CN (1) | CN109475522A (en) |
AU (2) | AU2016401508B2 (en) |
CA (1) | CA3058479A1 (en) |
IL (1) | IL262143A (en) |
RU (1) | RU2018137897A (en) |
SG (1) | SG11201808777UA (en) |
WO (1) | WO2017173474A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3058492A1 (en) * | 2016-04-06 | 2017-10-12 | Noxopharm Limited | Radiotherapy improvements |
AU2017247008B2 (en) | 2016-04-06 | 2022-04-07 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
EP4125870A1 (en) | 2020-03-30 | 2023-02-08 | Noxopharm Limited | Methods for the treatment of inflammation associated with infection |
WO2022204757A1 (en) * | 2021-03-30 | 2022-10-06 | Noxopharm Limited | Improved isoflavone formulation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO203996A0 (en) * | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
US8178123B2 (en) * | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
CA2492754C (en) * | 2002-07-24 | 2018-05-22 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
AU2002951833A0 (en) * | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
US20060167037A1 (en) | 2003-11-19 | 2006-07-27 | Kelly Graham E | Combinational radiotherapy and chemotherapy compositions and methods |
DE102005009515A1 (en) * | 2005-02-25 | 2006-09-07 | Exner, Heinrich, Dr. | A process for preparing a preparation of a DMSO-containing solid silicone oil emulsion for binding reactive oxygen compounds in the body of humans and animals |
EP1948103A2 (en) * | 2005-09-15 | 2008-07-30 | UMD, Inc. | A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration |
WO2009003229A1 (en) * | 2007-06-29 | 2009-01-08 | Novogen Research Pty Ltd | 2-substituted isoflavonoid compounds, medicaments and uses |
CA2738328A1 (en) * | 2008-08-29 | 2010-03-04 | Novogen Research Pty Ltd | Immunomodulating activities |
KR20110004525A (en) * | 2009-07-08 | 2011-01-14 | 동의대학교 산학협력단 | Composition for treatment of liver cancer comprising genistein and trail |
-
2016
- 2016-07-28 JP JP2019503595A patent/JP2019510830A/en active Pending
- 2016-07-28 US US16/091,688 patent/US20190160004A1/en not_active Abandoned
- 2016-07-28 SG SG11201808777UA patent/SG11201808777UA/en unknown
- 2016-07-28 AU AU2016401508A patent/AU2016401508B2/en not_active Ceased
- 2016-07-28 EP EP16897482.2A patent/EP3439651A4/en not_active Withdrawn
- 2016-07-28 WO PCT/AU2016/050674 patent/WO2017173474A1/en active Application Filing
- 2016-07-28 RU RU2018137897A patent/RU2018137897A/en not_active Application Discontinuation
- 2016-07-28 EP EP21176052.5A patent/EP3939583A1/en not_active Withdrawn
- 2016-07-28 KR KR1020187032107A patent/KR20190016017A/en unknown
- 2016-07-28 CN CN201680086470.1A patent/CN109475522A/en active Pending
- 2016-07-28 CA CA3058479A patent/CA3058479A1/en not_active Abandoned
-
2018
- 2018-10-04 IL IL262143A patent/IL262143A/en unknown
-
2020
- 2020-06-23 AU AU2020204172A patent/AU2020204172A1/en not_active Abandoned
-
2021
- 2021-05-24 US US17/328,041 patent/US20210338576A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2019510830A (en) | 2019-04-18 |
EP3439651A1 (en) | 2019-02-13 |
US20190160004A1 (en) | 2019-05-30 |
US20210338576A1 (en) | 2021-11-04 |
KR20190016017A (en) | 2019-02-15 |
EP3439651A4 (en) | 2019-10-30 |
CA3058479A1 (en) | 2017-10-12 |
WO2017173474A1 (en) | 2017-10-12 |
RU2018137897A (en) | 2020-05-13 |
IL262143A (en) | 2018-11-29 |
CN109475522A (en) | 2019-03-15 |
EP3939583A1 (en) | 2022-01-19 |
AU2020204172A1 (en) | 2020-07-09 |
AU2016401508A1 (en) | 2018-11-01 |
RU2018137897A3 (en) | 2020-05-13 |
AU2016401508B2 (en) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804934PA (en) | Novel Compounds | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201805835WA (en) | Modified oncolytic virus | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201803906PA (en) | Control of cellular redox levels | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201810177VA (en) | Pet-imaging immunomodulators | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201805755SA (en) | Methods of administering hepcidin | |
SG11201808777UA (en) | Improvements in cancer treatment |